- Market Capitalization, $K 813,063
- Shares Outstanding, K 92,184
- Annual Sales, $ 35,220 K
- Annual Income, $ -152,600 K
- 60-Month Beta 1.12
- Price/Sales 23.53
- Price/Cash Flow N/A
- Price/Book 66.60
|Period||Period Low||Period High||Performance|
| || |
-1.04 (-11.79%)since 07/07/20
| || |
+3.24 (+71.37%)since 05/07/20
| || |
+4.79 (+160.20%)since 08/07/19
Dynavax Technolo (NASDAQ:DVAX) traded in a range yesterday that spanned from a low of $7.08 to a high of $8.23. Yesterday, the shares fell 11.8%, which took the trading range below the 3-day low of $8.52...
Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -12.50% and -53.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
EMERYVILLE, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Thursday reported a loss of $51.6 million in its second quarter.
-- Multiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications, including COVID-19
Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib
, /PRNewswire/ -- The pandemic has drastically changed the world's social and economic landscape. Countries have shut down schools and businesses, restricted travel, postponed entertainment and sporting...
Hopes of a vaccine have once again started rising with a number of companies now entering the final phase of their trials.
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, IBIO, DVAX, AAPL, and DIS.
-- TriSalus plans to further develop SD-101 as an oncology therapeutic
Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August...